Nanobiotix S.A.
Nanobiotix S.A.
Your view on NBTX
Overview
What the company does, where it operates, and who runs it.
About Nanobiotix S.A.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laurent Levy
- Headquarters
- 60 rue de Wattignies, Paris, FR
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laurent Levy
- Headquarters
- 60 rue de Wattignies, Paris, FR
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.
Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
The company was incorporated in 2003 and is headquartered in Paris, France.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nanobiotix S.A., and the rating behind it. NBTX last traded at $37.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nanobiotix S.A.. Starting points for Nanobiotix S.A.: EPS -$0.51, beta 0.57 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nanobiotix S.A.. Nanobiotix S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nanobiotix S.A.. Trailing twelve-month EPS for Nanobiotix S.A. stands at -$0.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nanobiotix S.A.. Nanobiotix S.A. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nanobiotix S.A. valued side by side against its closest peers. Nanobiotix S.A. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nanobiotix S.A., and how their positions are changing. At a $1.87B market value, institutional positions materially move Nanobiotix S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nanobiotix S.A. executives and directors. Shares of Nanobiotix S.A. have traded between $2.76 and $30.35 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nanobiotix S.A.. Nanobiotix S.A. is a $1.87B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nanobiotix S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nanobiotix S.A.. Coverage tracks Nanobiotix S.A. within Biotechnology (Healthcare). Press releases and market coverage, newest first.